[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist

Day 1

Major Challenges and Opportunities Facing Us in 2023
Moderator: Zhongxing Liao, MD, FASTRO, MD Anderson Cancer Center, Houston [R]

• What Should be the Treatment if Patients Become Unresectable after Neoadjuvant Immunotherapy?
  • Jessica Donington, MD, MSCR, UChicago Medicine, Chicago [S]
• Resistance for ICI Immunotherapy: Challenges and Opportunities
  • ​Jianjun Zhang, MD, PhD, MD Anderson Cancer Center, Houston [M]
• Q&A

The Emerging Benefits of Immunotherapy and Targeted Therapy
Moderator: Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center, New York [M]

• Stage I SBRT + Immunotherapy
  • Narek Shaverdian, MD, Memorial Sloan Kettering Cancer Center, New York [R]
• Phase II iSABR Results
  • Joe Chang, MD, PhD, MS, FASTRO, MD Anderson Cancer Center, Houston [R]
• ADCs and Bispecific mAbs
  • ​Sally Lau, MD, NYU Langone Health, Brooklyn, New York [M]
• Non-TKI Targeted Therapies KRAS, BRAF, and Beyond
  • ​Jia Luo, Dana-Farber Cancer Center, Boston [M]
• Q&A

Pearls, Pitfalls and Challenges in Toxicities Associated with Immunotherapy and Targeted Therapies: What We Know Now
Moderator: Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]

• Emerging Challenges in Immunotherapy and Targeted Therapy: Combination Therapies, Drug Resistance and Drug Rechallenge, Who? How? When?
  • Abdul Rafeh Naqash, MD, Johns Hopkins University, Baltimore [Professor]
• Emerging Challenges in Immunotherapy and Targeted Therapy: Lung Toxicity Diagnosis, Risk Factors and Treatment
  • ​Karthik Suresh, MD, Johns Hopkins Medicine, Baltimore [Pulmonologist]
• Q&A

Modern Substance Use Disorders – ​What's NOT on the Med List?
Moderator: Linda Martin, MD, MPH, University of Virginia Health Systems, Charlottesville, Virginia [S]

• Nicotine Addiction, and How to Properly Prescribe Tobacco Cessation Meds
  • ​Matthew Steliga, MD, UAMS Health, Little Rock, Arkansas [S]
• Non-Rx Drugs - The Good, the Bad and the Ugly – Impact on Cancer Treatments
  • Deepti Behl, MD, Sutter Medical Center, Sacramento, California [M]
• Panel Discussion and Q&A

Early Detection
Moderator: Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina [M]

• Screening Criteria and Models: Who is Included and Excluded and How to Apply the Current Models
  • ​Julie Wu, MD, PhD, Stanford University, Palo Alto, California [M]
• Screening Outside the NLST Patient Population
  • Elaine Shum, MD, NYU Langone Health, New York [M]
• Blood Based Testing for Screening
  • Aadel Chaudhuri, MD, PhD, Washington University, St. Louis [R]
• Q&A

Plenary Abstract Session
Moderator: David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]

• Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
  • David A. Palma, MD, PhD, Western University, London, Ontario, Canada
  • Discussant: Jeremy Brownstein, MD, MS, The Ohio State University Wexner Medical Center, Columbus, Ohio
• A Population-Based Analysis of the Management of Symptoms of Depression Among Patients with Stage IV Non-Small Cell Lung Cancer in Ontario, Canada
  • Vivian S. Tan, MD, Western University, London, Ontario, Canada
  • Alan Valentine, MD, FAPOS, The University of Texas MD Anderson Cancer Center, Houston, Texas
• Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  • Geoffrey Liu, MD, Princess Margaret Cancer Centre, University Health Network, Ontario, Canada​
  • Discussant: Aadel Chaudhuri, MD, PhD, Washington University, St. Louis
• Lung Cancer Survival Trends in the Veterans Health Administration
  • Drew Moghanaki, MD, MPH, VA Greater Los Angeles Healthcare System, Los Angeles
  • Discussant: Biniam Kidane, MD, MS, University of Manitoba, Manitoba, Canada

The Changing Landscape of Lung Cancer Biomarkers
Moderator: Kurt Schalper, MD, Yale University, New Haven, Connecticut [Surgical Pathologist]

• Current and Future Biomarkers for Immunotherapy, Targeted Therapies and ADCs in NSCLC
  • Kurt Schalper, MD, Yale University, New Haven, Connecticut [Surgical Pathologist]
• Molecular Classification and Novel Biomarkers for Small-Cell Lung Cancer
  • ​Triparna Sen, PhD, Mount Sinai, New York [Professor]
• Role of Pathologic Response Assessment and Non-Invasive Biomarkers/Liquid Biopsy in Resectable NSCLC
  • Sanja Dacic, MD, PhD, Yale University, New Haven, Connecticut [Pathologist]
• Role of Digital Pathology and Advanced Computational Analysis/AI in Lung Cancer Management
  • ​Anant Madabhushi, PhD, Emory University, Atlanta [R]
• Q&A

Day 2

Perioperative and Postoperative Therapies for Resectable Lung Cancer
Moderator: David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]

• Targeted and Immunotherapies in Surgically Resectable Non-small Cell Lung Cancer
  • Marina Garassino, MD, University of Chicago Medicine, Chicago [M]
• Impact of Perioperative Therapies on the Surgical Management of Lung Cancer
  • Neel Chudgar, MD, Montefiore Medical Center, New York [S]
• The Role of Radiation in Surgically Resectable Lung Cancer
  • Jeremy Brownstein, MD, The Ohio State University, Columbus, Ohio [R]
• Q&A

Impact of Frailty and Other Co-Morbidities on Lung Cancer Outcomes
Moderators: Philip Linden, MD, University Hospitals Cleveland Medical Center, Cleveland [S]
Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]

• How to Assess Fitness for Lung Resection
  • Leonidas Tapias, MD, University Hospitals Cleveland Medical Center, Cleveland [S]
• Comorbidity and Frailty Considerations with Systemic Therapy
  • Mehmet Altan, MD, MD Anderson Cancer Center, Houston [M]
• Comorbidity and Frailty Considerations with Chemoradiation
  • Pranshu Mohindra, MD, University Hospitals Cleveland Medical Center, Cleveland [R]
• Q&A

Oligometastatic NSCLC: Current Evidence and Future Directions
Moderator: Kristin Higgins, MD, Emory University, Atlanta [R]

• Current Data and Clinical Trials that Will Define the Role in RT in Oligometastatic Disease
  • Daniel Gomez, MD, MBA, Memorial Sloan Kettering Cancer Center, New York {R]
• Potential Biomarkers for Patient Selection in Oligometastatic Space
  • Puneeth Iyengar, MD, University of Texas Southwestern Medical Center, Dallas [R]
• Discussion and Q&A

Finding and Removing Small Nodules – Keeping Up with Technological Advances
Moderator: Biniam Kidane, MD, MS, University of Manitoba, Winnipeg, Manitoba, Canada [S]

• The State of Evidence regarding Sublobar Resection for Small Early-Stage Lung Cancer
  • ​Anna McGuire, MD, MSc, FRCSC, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada [S]
• Robotic Bronchoscopy and Navigational Bronchoscopy to Find Small Nodules
  • Otis Rickman, DO, Ascension St. Thomas Hospital Midtown, Nashville, Tennessee [Professor]
• Molecular Localization of Lung Nodules
  • ​Doraid Jarrar, MD, FACS, FCCP, Penn Medicine, Philadelphia [S]
• Q&A

Oral Abstract Session
Moderator: Zhongxing Liao, MD, FASTRO, MD Anderson Cancer Center, Houston [R]

• KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
  • Marcelo Negrao, MD, MD Anderson Cancer Center, Houston
• Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
  • Alexander Sasse, Yale School of Medicine, New Haven, Connecticut
• Esophagitis Following Intensity-Modulated Radiotherapy for Lung Cancer
  • Nathaniel Miller, MD, Virginia Commonwealth University, Richmond
• Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis
  • Tian Xiao, MD, Western University, Ontario, Canada
• Clinical, Quality of Life and Cost Outcomes in Patients with Early Stage Non-small Cell Lung Cancer Undergoing Surgery or SBRT
  • Sowmy Thuppal, MD, PhD, Southern Illinois University, Springfield, Illinois
• Disparities in Delivery of Local-consolidative Surgery for Patients with Single-site Oligometastatic Non-small Cell Lung Cancer
  • Jorge Humberto Rodriguez-Quintero, MD, Montefiore Medical Center, Bronx, New York
• Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
  • Alexander Sasse, Yale School of Medicine, New Haven, Connecticut

​​​​​​​
Review/Update on Thymic Malignancy and Mesothelioma
Moderator: Stephen Chun, MD, MD Anderson Cancer Center, Houston [R]

• Surgical Considerations in Resectability for Mesothelioma and Thymic Tumors
  • ​Andrea Wolf, MD, Mount Sinai, New York [S]
• Postoperative Radiotherapy Field Design for Mesothelioma and Thymic Tumors
  • Quynh-Nhu Nguyen, MD, MD Anderson Cancer Center, Houston [R]
• Systemic Therapy Updates for Mesothelioma and Thymic Tumors
  • ​Matthew Gubens, MD, MS, University of California, San Francisco [M]
• Q&A

​​​​​​​​​​​​​​Novel Approaches in Limited Stage and Extensive Stage Small Cell Lung Cancer
Moderator: Percy Lee, MD, FASTRO, City of Hope, Irvine, California [R]

• Molecular Subclassification and Implications in SCLC Personalized Therapy
  • Jyoti Malhotra, MD, MPH, City of Hope, Irvine, California [M]
• Novel Advances in Radiotherapy for SCLC
  • Kristin Higgins, MD, Emory University, Atlanta [R]
• Role of Brain Directed Radiotherapy for SCLC in 2023
  • ​Vinai Gondi, MD, Northwestern Medicine Cancer Center, Warrenville, Illinois [R]
• Q&A

Day 3

​​​​​​​Stage III: Innovation on the "Big Stage"
Moderator: Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]

• Neoadjuvant Therapy for Resectable Stage III
  • ​Linda Martin, MD, MPH, University of Virginia Health Systems, Charlottesville, Virginia [S]
• Adjuvant Therapy for Resectable Stage III
  • Salma Jabbour, MD, FASTRO, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey [R]
• Immunotherapy in Unresectable Stage III
  • Steven Lin, MD, PhD, MD Anderson Cancer Center, Houston [R]
• Targeted Therapy in Unresectable Stage III
  • ​Carl Gay, MD, PhD, MD Anderson Cancer Center, Houston [M]
• Q&A

Sexual Health and Fertility Preservation Under Psychosocial Oncology
Moderator: Kristin Rojas, MD, FACS, University of Miami Health System, Miami [S]

• Speaker: Terri Woodard, MD, MD Anderson Cancer Center, Houston [Professor]

Difficult Discussions – Prognosis, Therapeutic Choices, End of Life
Moderator: Madison Grogan, MPH, The Ohio State University, Columbus, Ohio [M]

• Discussing Phase I Clinical Trials with Patients with Advanced NSCLC: Challenges and Opportunities
  • ​Jennifer Carlisle, MD, Emory University, Atlanta [M]
• Tools to Improve Communication between Physicians and Patients
  • Kate Schueller, MD, University of Wisconsin, Madison, Wisconsin [M]
• Integration of Early Palliative Care to Improve Outcomes in Patients with NSCLC
  • ​Madison Grogan, MPH, The Ohio State University, Columbus, Ohio [M]
• Financial Toxicity
  • ​Meera Ragavan, MD, Kaiser Permanente, San Francisco [M]
• Q&A

​​​​​​​​​​​​​​​​​​​​​Symposium Key Takeaways and What's Coming Down the Pipeline
Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]